Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Optimi Health Corp. (C:OPTI)

Business Focus: Health Food Stores

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for OPTI within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 29, 2024 08:00 ET
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as psilocybin and MDMA, is pleased to announce that it has received...
Read full article
May 22, 2024 08:30 ET
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI)...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
159.38
1.64
1.60
Price to Book - most recent quarter
3.02
2.23
1.97
Price to Cash Flow per share - TTM
--
--
7.57
Price to Free Cash Flow per share - TTM
--
--
14.80
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 15, 20249,071-15,766
Apr 30, 202424,83723,658
Apr 15, 20241,179-8,345
See Short Report

Business Summary

Sector:  Consumer Cyclicals Industry:  Miscellaneous Specialty Retailers

Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.

See business summary

 

Twitter

Search (past week) for $OPTI.CA

  • No tweets found